NEW ORLEANS — A novel monoclonal antibody could become the first treatment for multicentric Castleman's disease (MCD), according to data presented here at the American Society of Hematology 55th ...
LITTLE ROCK – The first-ever treatment for a rare blood disorder called multicentric Castleman's disease was approved recently by the Food and Drug Administration after drug trials headed by a ...
Castleman's disease represents a spectrum of rare lymphoproliferative disorders that share common histopathological features yet exhibit diverse clinical presentations. Traditionally divided into ...
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended that siltuximab (Sylvant, Janssen) be granted marketing authorization for the treatment of ...
The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman's disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes) ...
Castleman disease is a rare condition that affects your body’s lymph nodes, causing one or more of them to enlarge. Castleman can become life threatening if not treated, causing infection and organ ...
T-Cell–Depleted Reduced-Intensity Transplantation Followed by Donor Leukocyte Infusions to Promote Graft-Versus-Lymphoma Activity Results in Excellent Long-Term Survival in Patients With Multiply ...
Background A 35-year -old man presented to a local emergency room with acute left-flank pain and a medical history of nephrolithiasis. There were no aggravating or relieving factors for the left-flank ...
At study entry, the median time from MCD diagnosis was 21 months. All patients had stable disease on chemotherapy and were dependent on chemotherapy for a median time of 13 months. The median CD4 cell ...
David Fajgenbaum and Grant Mitchell unveil Every Cure at Clinton Global Initiative. The organization, Every Cure, is cofounded with Grant W Mitchell, MD, MBA and Tracey Dikora to create a novel end-to ...
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare ...
The U.S. Food and Drug Administration has approved Sylvant (siltuximab) to treat multicentric Castleman’s disease. MCD is a rare disorder that causes an abnormal overgrowth of immune cells in lymph ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback